CHEK1 and Ewing sarcoma: We identified that the combination of gemcitabine with a CHK1 inhibitor (LY2603618) was more effective at inhibiting Ewing sarcoma cell growth than the combination of gemcitabine with an ATR inhibitor (AZ20).